The risk of diminished anti-tumour activity should therefore be kept in mind whenever initiating clinical trials with HDAC blocking compounds [25], particularly as Akt phosphorylation is inducible by different HDAC inhibitors with variable chemical structures [24]. Here, HDAC9 is linked to neoplasm.